Liver disease belongs in the first conversation about sermorelin, even if your main concern is tiredness, poor sleep, or a low hormone result. Tell the clinician what condition you have, who follows it, and whether recent tests or symptoms have changed.
A low IGF-1 result is not automatically proof of adult growth hormone deficiency. The Endocrine Society notes that other problems, including liver disease, can lower IGF-1. That is a reason for clinical interpretation, not a reason to start a hormone-related medicine from a lab number alone.
Explain the liver diagnosis and let the care team interpret hormone results in context. There is no universal liver-safe sermorelin dose established by these sources.
Clarify the liver history rather than using one broad label
An elevated liver enzyme result, fatty liver disease, hepatitis, and cirrhosis do not all describe the same condition. Bring the diagnosis your clinician has given you and any relevant recent reports. If the cause of an abnormal result is still being investigated, tell the sermorelin prescriber that the evaluation is incomplete.
NIDDK describes history, examination, blood tests, and imaging among the tools used to evaluate cirrhosis. That discussion should not be read as saying everyone with liver disease has cirrhosis. The consultation checklist can help you organize what is known and what still needs review.
A low IGF-1 result needs an explanation
The Endocrine Society's patient information identifies liver disease and low body weight among alternative reasons for low IGF-1. A result therefore needs to be considered with your medical history and the clinical reason for testing. It does not select a treatment on its own.
Ask whether an endocrinology assessment is appropriate and which findings would actually support growth hormone deficiency. The adult deficiency guide explains why diagnosed pituitary disease differs from general aging complaints. Raising a laboratory value is not the same as establishing that a treatment improves the health problem behind it.
Review the full list of medicines and products
NIDDK advises people with cirrhosis to discuss prescription medicines, over-the-counter products, supplements, and herbal remedies with their clinician. Include sleep products and pain relievers as well as any other hormone or peptide treatment. Do not assume something sold as natural is irrelevant to a medication review.
This is general liver-care guidance, not proof that sermorelin causes a particular liver injury. The drug-interaction guide helps prepare the list. Do not stop a medicine used to manage your liver condition because a wellness advertisement suggests a different explanation for symptoms.
Separate proposed benefits from liver treatment
The sources reviewed for this guide do not establish compounded sermorelin as a treatment for cirrhosis or other liver disease. An account of growth hormone biology, an improvement in body composition, or a study of another drug cannot by itself establish that a particular sermorelin preparation treats your liver condition.
Ask what evidence supports the specific proposed use and what alternatives address the actual diagnosis. FDA's compounding guidance also makes clear that a compounded medicine is not an FDA-approved finished product. A seller's claim about metabolism should not be used to replace disease-specific care.
Do not invent a liver-adjusted dose
We have not found a validated hepatic adjustment schedule in the sources used here. That absence does not establish a safe standard dose, a particular reduced dose, or a blanket prohibition for every liver condition. Whether treatment is appropriate requires an individualized clinical decision.
Ask the prescriber how the liver history affects that decision and whether coordination with your liver specialist is needed. Our dosage guide explains why internet charts cannot substitute for a prescription. The concentration on a vial helps identify a preparation; it does not answer whether the proposed treatment is suitable.
Agree on follow-up and how to report changes
Before starting anything new, ask who will review symptoms and tests, how records will be shared, and what findings would change the plan. Follow the instructions from the clinician managing your liver disease about urgent symptoms and ongoing care. A portal message is not a substitute for emergency assessment when it is needed.
Keep the prescription label and an up-to-date medicine list available for any clinician evaluating a change. The side-effect guide can help you describe timing without assuming the cause. If the proposal remains unclear, ask for clarification before committing to a longer supply.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- NIDDK: Diagnosis of cirrhosisGovernment or medical organization guidance · History, blood tests, and imaging; not a home diagnostic checklist. Checked September 22, 2026.
- FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
- Endocrine Society: Growth hormone deficiencyMedical organization patient information · Childhood and adult disease sections are distinct; adult risk factors and prescribed GH replacement are the relevant material.
- Endocrine Society: Adult growth hormone deficiencyClinical practice guideline · Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
- NIDDK: Treatment for cirrhosisGovernment or medical organization guidance · Medication discussion and disease-specific care; not a sermorelin trial. Checked September 22, 2026.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.
- HHS: your medical recordsUS government · Patient access and correction rights; not a guarantee of prescription transfer or continuation. Checked September 21, 2026.